Thromgen was founded around initial technology conceived at Temple University and the University of Michigan, where the patent portfolio was developed. The firm is a privately owned early-stage biotechnology company that is discovering and developing novel treatments for diseases related to a new class of thrombin receptor inhibitors (also called antagonists or blockers). The novel mechanisms of the technology allows Thromgen's therapeutic scope to include cardiovascular-, oncologic-, and inflammatory-related diseases. Initially, the Company is focusing on acute coronary syndromes and prostate cancer with its lead candidate, thrombostatinTM.
